Clinical Trials Browser

Alpelisib × 90 days × Clear all

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

Ovarian Neoplasms

NCT05022342 2026-02-23

SPEAR

Breast Neoplasms

NCT05038735 2026-02-20

EPIK-B5

Phase 3 Active not recruiting

Breast Neoplasms

NCT05983159 2026-02-19

TARGET-VM

Phase 2 Recruiting

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

NCT05948943 2026-02-13

EPIK-L1

Phase 2/3 Recruiting

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

NCT05101564 2026-02-12

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Phase 2 Completed

19 enrolled 10 charts

Breast Neoplasms

NCT05501886 2026-02-10

VIKTORIA-1

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT05646862 2026-02-05

INAVO121

Phase 3 Active not recruiting

Breast Neoplasms

NCT04208178 2026-02-02

EPIK-B2

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

NCT01872260 2026-01-30

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05933395 2026-01-20

GERTRUDE

Phase 2 Recruiting

Neoplasm Metastasis

NCT03056755 2026-01-13

BYLieve

Phase 2 Completed

383 enrolled 16 charts

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT04524000 2026-01-12

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Phase 2 Active not recruiting

Advanced Breast Cancer

NCT04762979 2026-01-02

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Phase 2 Active not recruiting

Hormone Receptor Positive Breast Carcinoma

NCT06083038 2025-12-31

Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib

Active not recruiting

Breast Neoplasms, Hyperglycemia

NCT04997902 2025-12-23

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Phase 1/2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence